Related Experiment Videos
Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms
Insights
Diltiazem, nifedipine, and verapamil are calcium channel blockers with distinct cardiovascular effects. Despite inhibiting calcium entry, they differ in heart rate, conduction, and inotropic state impacts, with potential benefits in myocardial ischemia.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Calcium channel blockers (CCBs) are crucial cardiovascular drugs.
- Diltiazem, nifedipine, and verapamil are major CCBs inhibiting calcium entry into excitable cells.
Purpose of the Study:
- To compare the cardiovascular effects of diltiazem, nifedipine, and verapamil.
- To elucidate differences in their actions on heart rate, atrioventricular conduction, and myocardial inotropic state.
Main Methods:
- Equieffective vasodilator doses of diltiazem, nifedipine, and verapamil were evaluated.
- Effects on coronary blood flow, inotropic state (in vitro and in vivo), atrioventricular conduction, heart rate, and baroreceptor reflex were assessed.
- Studies were conducted in isolated tissues and in anesthetized and conscious animal models.
Main Results:
- All drugs increased coronary blood flow dose-dependently (nifedipine > diltiazem = verapamil).
- Inotropic effects varied: verapamil > nifedipine > diltiazem in vitro; nifedipine increased, verapamil decreased, diltiazem had minimal effect in conscious dogs.
- Diltiazem and verapamil slowed A-V conduction; nifedipine did not.
- Heart rate responses differed between anesthetized and conscious states.
- Nifedipine showed significant baroreceptor reflex interference.
- All CCBs demonstrated potential to retard myocardial damage during ischemia.
Conclusions:
- Diltiazem, nifedipine, and verapamil exhibit distinct cardiovascular profiles despite a common mechanism of action.
- Differences in effects on heart rate, A-V conduction, and inotropic state are significant.
- Potential anti-ischemic properties warrant further investigation.
Abstract:
The three major calcium channel blocking agents, diltiazem, nifedipine and verapamil, inhibit calcium entry into excitable cells. Despite this apparent common action at the cell membrane, these drugs produce quantitative and frequently qualitative differences in cardiovascular variables (for example, heart rate, atrioventricular [A-V] conduction and myocardial inotropic state) when evaluated at equieffective vasodilator doses. All three drugs increase coronary blood flow in a dose-dependent fashion (nifedipine greater than diltiazem = verapamil), and produce a negative inotropic effect in vitro in isolated atria and ventricles, also in a dose-dependent manner (verapamil greater than nifedipine greater than diltiazem). However, in conscious dogs nifedipine increases, verapamil decreases and diltiazem has little effect on the inotropic state. A-V conduction is slowed by diltiazem and verapamil but not by nifedipine in anesthetized dogs and in conscious dogs as judged from the P-R interval in the electrocardiogram. Heart rate is slowed in pentobarbital-anesthetized animals but is accelerated in conscious dogs (nifedipine greater than verapamil greater than diltiazem). Nifedipine also appears to interfere significantly with the arterial baroreceptor reflex by an apparent vagolytic action that is less evident with diltiazem and verapamil. Diltiazem, and possibly verapamil and nifedipine as well, appears to retard myocardial damage that accompanies ischemia. The mechanisms and sites of action of these drugs are presumed to be at the cell membrane; however, intracellular sites may also be involved.